GlassScriptPhysician profile
Arnold B Mellits
NPI 1851343289
$4,641.82
in general payments reported to CMS, 2019-2025
44 companies · $947 in 2025
The $947 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $183 · 2021: $241 · 2022: $729 · 2023: $826 · 2024: $695 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $635.33 | 2019-2025 | |
| Amgen INC. | $540.73 | 2019-2025 | Enbrel, Otezla, Otezla |
| Janssen Biotech, INC. | $434.73 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $433.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Ucb, INC. | $340.37 | 2019-2025 | Bimzelx, Cimzia, Rystiggo |
| Novo Nordisk INC | $283.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $281.24 | 2019-2024 | Saphnelo |
| Abbvie INC. | $235.33 | 2019-2023 | |
| Pfizer INC. | $184.06 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.97 | 2020-2024 | Ofev |
| Sanofi-Aventis U.S. LLC | $89.27 | 2024-2025 | |
| Astellas Pharma US INC | $78.78 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $61.08 | 2021-2024 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $59.73 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.36 | 2021-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.55 | 2023-2025 | Cologuard Collection Kit |
| Biogen, INC. | $44.41 | 2022-2025 | Leqembi |
| Dynavax Technologies Corporation | $41.82 | 2023-2024 | Heplisav-B |
| Eisai INC. | $41.26 | 2021-2025 | |
| Abbott Laboratories | $39.27 | 2020-2023 | Freestyle Libre 3 |
| Bausch Health US, LLC | $38.62 | 2022-2024 | Wellbutrin, Aplenzin |
| Sandoz INC. | $38.37 | 2023 | Hyrimoz |
| Teva Pharmaceuticals USA, INC. | $35.41 | 2019-2022 | |
| Celgene Corporation | $35.05 | 2019 | |
| Grifols USA, LLC | $34.82 | 2023 | Prolastin-C Liquid |
| Alnylam Pharmaceuticals INC. | $28.91 | 2023 | Onpattro |
| Argenx US, INC. | $28.28 | 2024 | Vyvgart Hytrulo |
| Inspire Medical Systems, INC. | $25.78 | 2025 | Inspire |
| Csl Behring | $25.39 | 2023 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $24.67 | 2025 | Rexulti |
| Vivus LLC | $23.84 | 2019 | |
| Smith+Nephew, INC. | $23.47 | 2025 | Redapt, Real Intelligence |
| Allergan, INC. | $21.54 | 2019 | |
| Acadia Pharmaceuticals INC | $20.86 | 2025 | Nuplazid |
| Alvogen INC | $20.71 | 2025 | Teriparatide |
| Genzyme Corporation | $20.62 | 2022 | |
| Amarin Pharma, INC. | $20.57 | 2019 | |
| Abiomed | $18.52 | 2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $17.99 | 2025 | Orencia |
| Fresenius Kabi USA, LLC | $17.39 | 2023 | Idacio |
| Upsher-Smith Laboratories LLC | $16.76 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.09 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $14.91 | 2020 | |
| Boston Scientific Corporation | $14.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Mellits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.